Azione PULM PULMATRIX, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Pulmatrix, Inc.

Azioni

PULM

US74584P3010

Mercato chiuso - Nasdaq
Altri mercati azionari
 22:30:00 03/05/2024 		Variaz. 5gg Var. 1 gen.
1,96 USD -3,44% Grafico intraday di Pulmatrix, Inc. -3,92% +5,38%
28/03 Pulmatrix, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023 CI
13/03 Pulmatrix, Inc. approva il licenziamento di Margaret Wasilewski come Chief Medical Officer CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
Pulmatrix Explores Strategic Alternatives
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Earnings Flash (PULM) PULMATRIX Reports Q2 Revenue $1.8M
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
Sector Update: Health Care Stocks Easing Late Tuesday
Sector Update: Health Care Stocks Lower Tuesday Afternoon
Pulmatrix Seeks FDA Approval to Launch Phase 2 Trial of Investigational Drug for Acute Migraine Treatment; Shares Rise
Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione PULM
  4. Notizie Pulmatrix, Inc.
  5. Altre lingue